Masimo (NASDAQ:MASI) Given New $205.00 Price Target at Wells Fargo & Company

Masimo (NASDAQ:MASI) had its target price lifted by Wells Fargo & Company from $193.00 to $205.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

Several other equities analysts have also commented on the company. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday. Finally, Piper Sandler lifted their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Performance

Shares of MASI stock opened at $190.34 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $10.19 billion, a PE ratio of 131.27 and a beta of 1.02. The company’s fifty day simple moving average is $172.56 and its 200-day simple moving average is $152.84. Masimo has a 52 week low of $101.61 and a 52 week high of $191.10.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, equities research analysts anticipate that Masimo will post 4.1 EPS for the current year.

Institutional Trading of Masimo

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its holdings in Masimo by 5,340.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock worth $319,000 after acquiring an additional 2,350 shares in the last quarter. State of Alaska Department of Revenue lifted its position in shares of Masimo by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 345 shares during the last quarter. SteelPeak Wealth LLC acquired a new position in Masimo in the third quarter worth about $570,000. Roubaix Capital LLC increased its holdings in Masimo by 37.0% in the third quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock valued at $4,539,000 after buying an additional 9,202 shares during the last quarter. Finally, Malaga Cove Capital LLC acquired a new stake in Masimo during the third quarter valued at approximately $401,000. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.